Ivermectin for onchocercal eye disease (river blindness) (Review)

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

42. ivomec$.tw. 43. exp albendazole/ 44. albendazole$.tw. 45. exp levamisole/ 46. levamisole$.tw. 47. or/39-46 48. 38 and 47 49. 32 and 48 Appendix 4. WHO International Trials Registry (ICTRP) search strategy onchocerc* AND ivermectin W H A T ’ S N E W Last assessed as up-to-date: 5 August 2009. 12 August 2009 New search has been performed Issue 4, 2009: Updated searches yielded no new trials. The background has been updated to include information on Loa loa infection (loaisis). Four studies are included instead of five as per the original published review as one report was of a subset of patients included in another trial. H I S T O R Y Protocol first published: Issue 3, 2000 Review first published: Issue 1, 2001 30 October 2008 Amended Converted to new review format. Ivermectin for onchocercal eye disease (river blindness) (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 38
C O N T R I B U T I O N S O F A U T H O R S Conceiving the review: RW Screening search results: HE, JE Screening retrieved papers against inclusion criteria: HE, ES, JE Appraising quality of papers: HE, ES, JE Abstracting data from papers: HE,JE Entering data into RevMan: HE, ES, JE Analysis of data: HE, RW,JE Writing the review: HE, RW,JE D E C L A R A T I O N S O F I N T E R E S T Jennifer Evans worked on one of the included trials - Abiose 1993. S O U R C E S O F S U P P O R T Internal sources • Institute of Ophthalmology, UK. External sources • British Council, UK. D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W The main difference between the protocol and review is that for the update in 2009 we moved to assessing the risk of bias using the Cochrane collaboration’s tool for assessing risk of bias (Higgins 2008). In particular, we updated the methods for assessing the effect of heterogeneity, missing data and selective outcome bias. I N D E X T E R M S Ivermectin for onchocercal eye disease (river blindness) (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 39
Page 1 and 2: Ivermectin for onchocercal eye dise
Page 3 and 4: [Intervention Review] Ivermectin fo
Page 7 and 8: B A C K G R O U N D Description of
Page 9 and 10: O B J E C T I V E S The primary obj
Page 11 and 12: H: Not mentioned but clinical judge
Page 13 and 14: tion in some cases. The assessments
Page 15 and 16: Allocation Abiose 1993 was the only
Page 17 and 18: Table 3. Outcome reporting grid Out
Page 19 and 20: Effects of interventions See: Summa
Page 21 and 22: Dadzie 1989 collected data on visua
Page 23 and 24: (Continued) Optic nerve disease New
Page 27 and 28: and there may well be bias due to i
Page 29 and 30: Gardon 2002 {published data only} F
Page 31 and 32: C H A R A C T E R I S T I C S O F S
Page 33 and 34: Dadzie 1989 Methods Method of alloc
Page 35 and 36: Taylor 1988 (Continued) Adequate se
Page 37 and 38: Characteristics of excluded studies
Page 39: 23. exp albendazole/ 24. albendazol

Ivermectin for onchocercal eye disease (river blindness) (Review)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?